An open-label phase 1 study to investigate SGN-CEACAM5C in adults with advanced solid tumors.
Principal Investigator
Dr. N. Steeghs
Drugs
Tusamitamab (PF-08046050/SGN-CEACAM5C) is a humanized IgG1 anti-CEACAM5 monoclonal antibody (mAb) conjugated to a topoisomerase I inhibitor – AMDCPT (aminomethyl-10,11-methylenedioxycamptothecin).
This clinical trial uses an experimental drug called PF-08046050. PF-08046050 is a type of antibody-drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells.
The study will test the safety of PF-08046050 in participants with solid tumors that are hard to treat or have spread throughout the body. This study will have 3 parts. Part A and Part B of the study will find out how much PF-08046050 should be given to participants. Part C will use the information from Parts A and B to see if PF-08046050 is safe and if it works to treat certain solid tumor cancers.
Read more on clinicaltrials.gov.
Additional comments
Escalation part for CRC, PDAC – open